Kenvue, the company behind Tylenol and a recent spinoff from Johnson & Johnson, is facing a significant public relations crisis as President Trump and others raise concerns about unproven links between the pain reliever and autism. This situation is critical not only for Kenvue's reputation but also for consumer trust in its products, especially as it recently made its debut on the New York Stock Exchange. How Kenvue navigates this challenge could set the tone for its future in the competitive pharmaceutical market.

Kenvue, the maker of Tylenol, has seen its stock plummet by 25% over the past six months amid rising concerns about a potential link between acetaminophen and autism. Despite Kenvue's strong denials of any connection and their expressed concern for the health risks to expecting mothers, the stock's decline reflects growing skepticism among investors. This situation is significant as it highlights the ongoing debate over the safety of common medications during pregnancy and the impact of public perception on pharmaceutical companies.